22157.jpg
The Worldwide Non-Opioid Pain Treatment Industry is Projected to Reach $47 Billion by 2030
October 19, 2022 07:28 ET | Research and Markets
Dublin, Oct. 19, 2022 (GLOBE NEWSWIRE) -- The "Non-Opioid Pain Treatment Market - Size & Forecasting to 2030" report has been added to ResearchAndMarkets.com's offering.The global non-opioid...
Outlook on the Topical Pain Relief Global Market to 2027 - Players Include Nestle, Novartis and Pfizer Among Others
June 17, 2022 07:58 ET | Research and Markets
Dublin, June 17, 2022 (GLOBE NEWSWIRE) -- The "Global Topical Pain Relief Market (2022-2027) by Therapeutic, Formulation, Formulation, Distribution Channel, Geography, Competitive Analysis, and the...
22157.jpg
Global Non-opioid Pain Patches Market Research Report (2021 to 2026) - by Patch Type, Distribution and Region
January 04, 2022 05:53 ET | Research and Markets
Dublin, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The "Non-opioid Pain Patches Market Research Report by Patch Type, by Distribution, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19"...
Conagen’s Novel Solution to Making Natural Capsaicin by Fermentation Accessible
April 22, 2021 12:23 ET | Conagen
Bedford, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Scalable, sustainable capsaicin ingredients for its use in food, consumer and industrial products have now become more accessible. Conagen...
22157.jpg
Global Topical Pain Relief Market (2020 to 2025) - Featuring Advacare Pharma, Endo International & Grunenthal Among Others
April 16, 2021 06:13 ET | Research and Markets
Dublin, April 16, 2021 (GLOBE NEWSWIRE) -- The "Topical Pain Relief Market" report has been added to ResearchAndMarkets.com's offering. This report is designed to be a helpful business tool that...
Berg Nutrition Brings a Unique Form of Pure Capsaicin Called aXivite to U.S. Marketplace
July 28, 2020 10:02 ET | Berg Nutrition
ANN ARBOR, Mich., July 28, 2020 (GLOBE NEWSWIRE) -- Berg Nutrition has been named the exclusive U.S. distributer of the branded ingredient, aXivite phenylcapsaicin, a synthetic, innovative form of...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial
June 19, 2019 07:00 ET | Sorrento Therapeutics, Inc.
Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group).Most...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration
April 10, 2019 09:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announces positive and better than initially hoped for top line results in a discovery study...
Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019
January 22, 2019 07:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the phase 1b study of its non-opioid, afferent nerve ablating drug candidate...